SUSTAINED GONADAL SUPPRESSION IN FERTILE WOMEN WITH THE LHRH AGONIST BUSERELIN

Hardt W, W Hardt, Wolfgang Hardt, M Schmidt-Gollwitzer, M. Schmidt‐Gollwitzer, Schmidt-Gollwitzer M
Clinical endocrinology · 1983 · vol. 19(5) , pp. 613–617 · doi:10.1111/j.1365-2265.1983.tb00039.x · PMID:6416718 · W2065279774
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-12 ⓘ

Intranasal buserelin achieved sustained chemical castration in fertile women by suppressing ovarian function, confirmed by hormonal parameters and endometrial biopsies, with immediate return of normal function after treatment cessation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Nine fertile women were treated with the luteinizing- hormone-releasing hormone agonist buserelin (seven women received 800 micrograms, two women 1200 micrograms intranasally for up to 24 weeks). Both doses produced sustained suppression of ovarian function, accompanied by hot flushes. In five women chemical castration was established within 1 to 5 weeks, whereas in the other four volunteers transient peaks of serum oestradiol occurred between the 6th and 19th weeks. Thereafter low postmenopausal oestradiol levels persisted. Chemical castration was confirmed by hormonal parameters and endometrial biopsies (inactive endometrium). After cessation of treatment normal cyclical function occurred immediately. This reversible chemical castration may be useful for new therapeutical approaches in sexual hormone dependent diseases (endometriosis, precocious puberty, metastatic breast cancer).

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Estradiol Buserelin Depression, Chemical Estradiol Female Fertility Fertility Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Luteinizing Hormone Luteinizing Hormone Progesterone Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (6)

Cited by (5)

Source provenance

europepmc
last seen: 2026-08-22T06:09:51.966504+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:55.985569+00:00
License: CC0 · commercial use OK